首页 › 基金 › MPM BioImpact LLC › GLUE
MPM BioImpact LLC 对 GLUE 的持仓历史
MONTE ROSA THERAPEUTICS INC · 医疗保健
MPM BioImpact LLC 在 Q2 2026 的 13F 申报中披露持有 GLUE(MONTE ROSA THERAPEUTICS INC)1,161,081 股,市值约 US$28.1M,约占其申报组合的 1.71%,在其申报持仓中市值排名第 23 位。 MPM BioImpact LLC 最近 3 个申报季度中有 3 个季度披露了 GLUE 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
MPM BioImpact LLC 对 GLUE 的持仓演变
MPM BioImpact LLC 于 Q4 2025 首次披露 GLUE 持仓:1,173,376 股(约 US$18.4M)。 该持仓在 Q2 2026 达到峰值 1,161,081 股,市值约 US$28.1M。 在 3 次申报中,MPM BioImpact LLC 0 次增持、1 次减持、1 次保持不变。 最近一期申报(Q2 2026)显示持股 1,161,081 股、市值约 US$28.1M,环比减持 -15,847 股。。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 1.17M | $18.40M | 新进 |
| Q1 2026 | 1.18M | $19.36M | 持有 |
| Q2 2026 | 1.16M | $28.10M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 GLUE 与 13F 数据
GLUE(MONTE ROSA THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 73 只申报持有 GLUE,申报仓位最大的包括:NEA Management Company, LLC (US$186.2M), TCG Crossover Management, LLC (US$111.9M), Vestal Point Capital, LP (US$111.3M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 GLUE 的基金
- NEA Management Company, LLC 7.69M 股 · $186.15M · Q2 2026
- TCG Crossover Management, LLC 4.62M 股 · $111.86M · Q2 2026
- Vestal Point Capital, LP 4.60M 股 · $111.32M · Q2 2026
- BVF INC/IL 4.46M 股 · $107.95M · Q2 2026
- BAKER BROS. ADVISORS LP 4.35M 股 · $105.17M · Q2 2026
- MONTANOVA CAPITAL, LLC 3.55M 股 · $85.90M · Q2 2026
- Versant Venture Management, LLC 3.18M 股 · $76.97M · Q2 2026
- BRAIDWELL LP 2.45M 股 · $59.33M · Q2 2026
- Aisling Capital Management LP 1.56M 股 · $37.65M · Q2 2026
- Bellevue Group AG 1.19M 股 · $28.80M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.00M 股 · $24.20M · Q2 2026
- Nextech Invest Ltd. 761.15K 股 · $18.42M · Q2 2026
更多关于 MPM BioImpact LLC
常见问题
How long has MPM BioImpact LLC held GLUE?
MPM BioImpact LLC has disclosed GLUE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is MPM BioImpact LLC's current position in GLUE?
As of Q2 2026, MPM BioImpact LLC holds 1.16M shares of GLUE (MONTE ROSA THERAPEUTICS INC), valued at $28.10M, representing 1.71% of its reported portfolio and ranking #23.
Has MPM BioImpact LLC been buying or selling GLUE?
In the latest 13F filing (Q2 2026), MPM BioImpact LLC reduced its position in GLUE. The position peaked in Q2 2026 at 1.16M shares.
Which other funds hold GLUE?
Other major institutional holders of GLUE include NEA Management Company, LLC, TCG Crossover Management, LLC, Vestal Point Capital, LP, among 73 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.